PT 617 - Alan Davis - Psychedelic Research and Patient Safety at Ohio State & Exploring Ibogaine's Potential

Psychedelics Today

Content provided by Psychedelics Today, LLC and Psychedelics Today. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Psychedelics Today, LLC and Psychedelics Today or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.

1M ago 1:15:17

MP3•Episode home

In this episode of Psychedelics Today, Joe Moore sits down with Alan Davis, Associate Professor at Ohio State University, to explore the evolving landscape of Ibogaine research and its therapeutic potential.

Alan offers a deep dive into the Iboga Patient Survey, a groundbreaking initiative collecting real-world data on the safety and efficacy of Ibogaine—particularly for those struggling with substance use disorders and mental health challenges. The conversation sheds light on the need for rigorous, community-informed research that could pave the way toward FDA approval and increased access for patients, including veterans dealing with trauma.

They also discuss the complexities of clinical trials, the tension between state and federal regulations, and the growing influence of corporate interests in psychedelic research. Alan emphasizes the importance of ethical transparency, community collaboration, and maintaining scientific integrity as the field grows.

If you're curious about the intersection of psychedelic medicine, clinical research, and patient safety, this is a must-listen episode.

Topics Covered

00:00 – Introduction and Guest Welcome
00:53 – Reflecting on COVID-19's Psychological Impact
01:29 – Introducing the Iboga Patient Survey
01:46 – History and Goals of Ibogaine Research
02:41 – Challenges in Conducting Clinical Trials
03:14 – Importance of Real-World Safety Data
06:55 – Personal Interest in Ibogaine
08:56 – Veterans and Trauma: A Personal Connection
10:53 – Reintegration and Emotional Processing
15:29 – Survey Participation and Accessibility
18:25 – Building Partnerships and Overcoming Challenges
21:06 – Ensuring Safety and Transparency
31:49 – Community and Academic Collaboration
33:06 – Survey Design and Future Research Directions
36:50 – Momentum in Psychedelic Research
37:48 – State vs. Federal Regulation
39:23 – Challenges in Psychedelic Treatment
43:01 – Corporate Interests and Scientific Objectivity
47:20 – Ketamine and Collaborative Research
51:56 – Ibogaine Patient Survey
57:55 – Psychedelics and Pain Research
01:07:22 – Conclusion and Future Directions

737 episodes

#Science #Medicine #Fitness #Psychedelics Today #Biology #Psychedelics Today, LLC #LSD #Map #Mushroom #Entheogenic #MDMA #Psychedelic